本报讯 （记者吴奕萱 见习记者王楠）2月10日晚间，浙江诚意药业股份有限公司（以下简称"诚意药业"）发布公告称，日 前，公司参与国家组织集采第一至八批协议期满品种接续采购申报，共有四款产品拟中选，分别为盐酸氨基葡萄糖胶囊、托拉 塞米注射液、盐酸利多卡因注射液和左卡尼汀注射液，采购周期均至2028年12月31日，覆盖全国区域。 （编辑 李波） 本次接续采购由全国各省份及新疆生产建设兵团组成采购联盟，委托江苏、河南、广东三省牵头开展全国统一采购，中选 药品将由医疗机构优先使用并确保完成约定采购量。公司核心产品盐酸氨基葡萄糖胶囊750mg规格本次报价与2025年销售均价 基本一致。 公告同时提示，本次拟中选最终结果仍存在不确定性；相关采购合同尚未签订，中标数量未明确，药品生产销售还受政 策、市场环境等因素影响，公司提醒投资者注意投资风险。 财务数据显示，盐酸氨基葡萄糖胶囊为公司主力品种，2024年实现营收3.35亿元，占总营收的46.88%；2025年前三季度营 收3.45亿元，占比达57.85%。其余三款产品营收占比相对较小。 ...

百川股份：近期部分主营产品涨价 2月10日晚，百川股份(002455)披露股票交易异动公告称，近期受市场供需关系因素影响，公司部分主 营产品的市场价格上涨，但由于产品价格波动的可持续性具有不确定性，暂时无法预计对公司业绩的影 响程度。近期除公司部分主营产品涨价外，公司经营情况及内外部经营环境未发生重大变化。 金诚信：拟追加收购CMH公司42.50%的股权 2月10日晚，金诚信(603979)发布公告称，公司拟在原交易安排收购CMH公司5%股权的基础上追加收购 CMH公司42.50%的股权。若本次交易顺利完成，公司将通过维理达资源公司持有CMH公司97.5%股 权，享有对CMH公司的最终控制权。 新瀚新材：拟定增募资不超10亿元 2月10日晚，新瀚新材(301076)发布公告称，拟向特定对象发行A股股票募集资金不超过10亿元，发行股 票数量不超过5246.44万股，扣除发行费用后的募集资金净额拟投资于年产8100吨高性能树脂、复合材 料及其配套工程建设项目、年产5000吨单体及其配套工程建设项目及高性能复合材料创新中心建设项 目。 中芯国际：2025年四季度实现销售收入24.89亿美元 环比增长4.5% 2月1 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 2026 年 2 月 9 日，浙江诚意药业股份有限公司（以下简称"公司"）参与 了国家组织集采第 1-8 批协议期满品种接续采购的申报，根据国家组织集采药 品协议期满品种接续采购办公室（以下简称"接续采购办公室"）于 2026 年 2 月 10 日发布的《国家组织集采药品协议期满品种接续采购拟中选结果表 （LC-YPJX-2026-1）显示，公司产品盐酸氨基葡萄糖胶囊、托拉塞米注射液、 盐酸利多卡因注射液和左卡尼汀注射液拟中选本次接续采购，现将相关情况公 告如下： | 序 | 药品 | 规格包 | 适应症 | 拟中选价格 | 拟中选 区域报 | | 采购周 | 拟中选 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 名称 | 装 | 用于治疗和预防 | | 量 | | 期 | 区域 | | | | 750mg* 120 粒/ | 全身所有部位的 骨关节炎，包括膝 关节、肩关节、髋 | | | | | ...

证券日报网讯2月9日，诚意药业（603811）在互动平台回答投资者提问时表示，公司会在定期报告披露 相应报告期末的股东人数。 ...

Group 1 - The core point of the article is that Chengyi Pharmaceutical (603811.SH) has a business of directly exporting raw materials to the European Union, although the revenue from EU exports has been a small proportion of the company's overall revenue in recent years [2]

Core Viewpoint - The company has successfully completed the registration process for Eicosapentaenoic Acid Ethyl Ester capsules and is preparing for compliance checks to begin production [1] Group 1: Regulatory Compliance - The company’s raw material production facility has passed multiple GMP audits by Australia's TGA since 1998, with the most recent GMP certificate obtained in January 2025 [1] - The facility has also successfully undergone on-site audits and re-evaluations by the US FDA, indicating its capability to produce the capsules in a GMP-certified environment [1] Group 2: Production Readiness - The Eicosapentaenoic Acid Ethyl Ester soft capsule has received the Drug Registration Certificate, and the production workshop is preparing for compliance checks [1] - Production can commence immediately after passing the compliance checks [1]

证券日报网讯1月12日，诚意药业（603811）在互动平台回答投资者提问时表示，2026年公司的研发投 入届时将在相关定期报告中披露。 ...

Group 1 - The core focus of the news is the establishment of the "Biopharmaceutical Innovation Alliance" in Qiantang District, aimed at addressing challenges in the biopharmaceutical industry such as long R&D cycles and complex intellectual property layouts [1][2] - Qiantang District has developed into a mature ecosystem for biopharmaceutical innovation, with over 1,800 companies in Hangzhou Medical Port, including 7 of the top 10 global pharmaceutical companies and 35 "quasi-unicorn" enterprises [2][3] - The alliance's theme is "AI + Biopharmaceuticals," aligning with national strategies in pharmaceutical technology, and aims to create a tighter collaboration network among industry, academia, and research [2][3] Group 2 - The biopharmaceutical industry in Qiantang has a revenue exceeding 50 billion yuan, supported by a 500 billion yuan industrial fund matrix to provide financial backing throughout the lifecycle of enterprises [3] - The region has established a preliminary industrial closed loop in the "AI + Biopharmaceutical" field, including AI target discovery, automated experiments, and digital clinical trials [2][3] - Qiantang District aims to achieve a biopharmaceutical industry scale exceeding 100 billion yuan by 2028, with a focus on collaboration among universities, platforms, enterprises, and the industry chain [3]

Group 1 - The core viewpoint of the article highlights the trading activity of Chengyi Pharmaceutical, which saw a closing price increase of 1.31% to 10.83 yuan on December 19 [1] - A significant block trade occurred, with a total volume of 831,000 shares and a transaction amount of 8.9997 million yuan, indicating a premium rate of 0.00% [1] - Over the past three months, the stock has recorded two block trades with a cumulative transaction amount of 20.4197 million yuan [1] Group 2 - In the last five trading days, the stock has experienced a cumulative increase of 1.31%, while the net outflow of main funds totaled 1.7795 million yuan [1]

格隆汇12月16日丨诚意药业(603811.SH)在投资者互动平台表示，近几年公司的原料药有向德国、西班 牙、意大利等欧盟国家出口。 ...